![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Wednesday, January 04, 2012 12:49:19 PM
_______________________________________
Morgan Stanley: Teva raised Copaxone price 15%
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) raised the price of its multiple sclerosis treatment Copaxone by 14.9% on January 3, states Morgan Stanley in a report on the specialty pharmaceutical industry. Teva also raised the list price of Azilect, for the treatment of Parkinson's disease, by 6%.
Copaxone is maintaining its US market share, accounting for over 35% of new prescriptions, and 40% of total prescriptions, despite the launch of Gilenya, an oral treatment made by Novartis AG (NYSE:NVS; LSE: NOV; SWX: NOVZ), in late 2010. Copaxone sales total $3.8 billion a year and reportedly account for a third to half of Teva's total profit.
Teva investors have been worried about possible generic versions of Copaxone, as well as the introduction of oral treatments for multiple sclerosis. However, the price hike suggests that Teva feels safe about its competitive position.
Published by Globes [online], Israel business news - www.globes-online.com - on January 4, 2012 - 4 January 12 17:01, Shiri Habib-Valdhorn
FEATURED North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • Jul 18, 2024 9:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM
Kona Gold Beverages Reaches Out to Largest Debt Holder for Debt Purchase Negotiation • KGKG • Jul 17, 2024 9:00 AM
Avant Technologies Welcomes Back Former CEO with Eye Toward Future Growth and Expansion • AVAI • Jul 17, 2024 8:00 AM
HealthLynked Expands Telemedicine Nationwide • HLYK • Jul 17, 2024 8:00 AM